{"id":"NCT00830128","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia","officialTitle":"An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For The Treatment Of Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2009-01-27","resultsPosted":"2012-02-14","lastUpdate":"2021-01-25"},"enrollment":106,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"pregabalin (Lyrica)","otherNames":[]}],"arms":[{"label":"pregabalin (Lyrica)","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety and efficacy of the long-term use of pregabalin at doses up to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study A0081208 (NCT00830167).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to 53 weeks","effectByArm":[{"arm":"Pregabalin","deltaMin":102,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":19,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081209&StudyName=A%20Long-Term%20Study%20To%20Evaluate%20Safety%20And%20Efficacy%20Of%20Pregabalin%20In%20Patients%20With%20Fibromyalgia"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":106},"commonTop":["Nasopharyngitis","Somnolence","Dizziness","Constipation","Weight increased"]}}